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Evaluation of Lowering the P Value Threshold for Statistical Significance From .05 to .005 in Previously Published Randomized Clinical Trials in Major Medical Journals
Lowering the threshold for statistical significance in medical research from a P value of .05 to .005 was recently proposed to reduce misinterpretation of study results.
1,2 P values less than .05 but greater than .005 would be reclassified as "suggestive." What effect this proposal would have on the medical literature is unclear. We evaluated primary end points in randomized clinical trials (RCTs) published in 3 major general medical journals with high impact factors to determine how the new threshold could affect the interpretation of previously published RCTs.
Methods | We searched PubMed from January 1, 2017, to December 31, 2017, for phase 3 RCTs published in JAMA, Lancet, and New England Journal of Medicine (NEJM). We excluded single-group trials, pooled analyses, RCTs without P values, and RCTs that used Bayesian or noninferiority analyses. Two authors (C. W., J. S.) screened all trials. We extracted data for primary end points because RCTs are most often powered for these end points. The following data were extracted from each trial: P values for primary end points (excluding subgroups), study title, journal name, funding source, sample size, type of intervention, whether the end point was mortality, whether the trial was multicentered, and whether the trial was multinational. Data were extracted blinded and in duplicate. Discrepancies were resolved by consensus.
We first determined the proportion of end points that would maintain statistical significance with a threshold of P less than .005 and that would be reclassified as suggestive (ie, P values >.005 but <.05). Second, we investigated trial characteristics associated with reporting at least 1 primary end point with a P value less than .005 using a logistic regression model adjusting for all extracted trial characteristics. We used Google Forms for data extraction and STATA version 13.1 (StataCorp) for the data analysis.
Results | Of 290 articles retrieved, 203 were included. The 87 excluded were mostly phase 1 or 2 trials (n = 26), noninferiority or Bayesian analyses (n = 26), or pooled analyses (n = 11) or did not report P values (n = 10). Characteristics of included RCTs are outlined in Table 1 . We identified 272 primary end points from 203 trials: 174 end points had a P value less than .05 and 98 had a P value greater than .05. Overall, 70.7% (123 of 174) of statistically significant primary end points were less than .005, whereas 29.3% (51 of 174) were between .005 and .05 and would be reclassified as suggestive. Of these 272 total P values, 53.5% (76 of 142) in NEJM, 47.7% (21 of 44) in Lancet, and 30.2% (26 of 86) in JAMA were less than .005.
We next analyzed the 203 trials to determine which trial characteristics were associated with reporting at least 1 P value less than .005. Before adjusting for covariates, industry funding, drug and "other" (eg, nonpharmacological) interventions, and trials published in NEJM and Lancet were associated with primary end points that met the new threshold for significance of P less than .005. Sample size, multicenter trials, multinational trials, and mortality end points were not related to maintaining statistical significance. After adjusting for covariates, only trials with industry funding (n = 86) were more likely to report primary end points that would maintain sta- 
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COMMENT & RESPONSE

Medications With Depression as an Adverse Effect
To the Editor In a cross-sectional survey study, Dr Qato and colleagues 1 found that the use of prescription medications with depression as a potential adverse effect was common. However, the authors did not take into account that most of the drugs described are used to treat conditions already linked to an increased risk of depressive symptoms. Although they investigated the relationship between hypertension and depression, they did not account for the association of depressive symptoms with pain (and subsequent use of pain killers), gastroesophageal reflux disorder (and subsequent use of gastrointestinal agents), or atopic disorders, such as asthma or allergic rhinitis (and the use of montelukast and antihistamines). Interestingly, these conditions are related to persistent lowgrade inflammation, 2 an important factor associated with depression, which could not be accounted for in the study. The increase in prescription of such drugs follows the increased prevalence and survival of people with chronic conditions in the United States.
3 In Table 1 in the article, the patients taking drugs associated with depression included more women, older people, widowed or divorced people, and people with higher levels of unemployment and obesity, factors also associated with an increased risk of depression in nonmedicated populations. This group also had more comorbidities, which may have additive inflammatory and psychological effects. People with more than 1 medical comorbidity tend to have more depressive symptoms, increasing with the number of disorders, without the etiology being related to adverse drug reactions.
4
The study did not investigate the converse-drugs that can be associated with a reduction in risk of depressive symptoms. Anti-inflammatory drugs or drugs for other conditions that exhibit anti-inflammatory properties, such as statins, acetylsalicylic acid, some hypoglycemic agents, drugs that act in the renin-angiotensin-aldosterone system, and immunomodulators, may have beneficial effects on mood, at least in subgroups of people.
